PMV Pharmaceuticals, Inc

PMVP · United States

Share price · PMVP

$1.22-0.02 (-1.61%) 3M

close as of 2026-11-18 · 24h delayed · vol 431K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PMVP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 26 Oct 2026-11.0%
  2. 30 Sep 2026+16.8%
  3. 14 Jul 2026+10.9%
  4. 15 Jun 2026-4.5%
  5. 27 Feb 2026+24.1%
  6. 26 Feb 2026+22.3%
  7. 10 Feb 2026+6.4%
  8. 29 Jan 2026-8.2%
  9. 18 Dec 2025+8.8%

    Nothing announced by PMVP that day or the session before.

    4 same-day headlines from peersCompare PMVP and its peers on a chart for this day
  10. 9 Dec 2025+6.0%

Share of unusual movement by asset

For each asset, the share of PMVP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
rezatapopt
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—19%
Other company news (earnings, financing, releases naming no asset)—8%
Sessions with no dated event—73%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
p53 reactivatorSmall molecule
Non-Small Cell Lung CancerBreast CancerOvarian Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
rezatapoptPhase 1/2Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer …
Est. primary completion 2026-12-15 · NCT04585750 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 August 2026Topline resultrezatapoptPYNNACLE Phase 2 pivotal: updated interim rezatapopt monotherapy data in ovarian cancer
PMV Pharmaceuticals, Inc · Source ↗
10 September 2025Topline resultrezatapoptInterim Phase 2 PYNNACLE data for rezatapopt

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$16M$20M+ $83M short-term inv.$34M-$18M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$15M$12M+ $67M short-term inv.$18M-$15M operating cash flowreport ↗
2026-Q1—$15M$39M+ $54M short-term inv.$18M-$20M operating cash flowreport ↗
2025-Q3—$18M$36M+ $93M short-term inv.$21M-$20M operating cash flowreport ↗
2025-Q2—$18M$44M+ $98M short-term inv.$21M-$18M operating cash flowreport ↗
2025-Q1—$17M$51M+ $109M short-term inv.$17M-$18M operating cash flowreport ↗
2024-Q3—$17M$49M+ $134M short-term inv.$19M-$17M operating cash flowreport ↗
2024-Q2—$15M$49M+ $164M short-term inv.$1.2M-$1.6M operating cash flowreport ↗
2024-Q1—$13M$48M+ $150M short-term inv.$15M-$16M operating cash flowreport ↗
2023-Q3—$14M$52M+ $150M short-term inv.$17M-$16M operating cash flowreport ↗
2023-Q2—$14M$68M+ $119M short-term inv.$17M-$13M operating cash flowreport ↗
2023-Q1—$15M$143M+ $86M short-term inv.$19M-$15M operating cash flowreport ↗
2022-Q3—$14M$100M+ $159M short-term inv.$18M-$17M operating cash flowreport ↗
2022-Q2—$11M$87M+ $190M short-term inv.$17M-$14M operating cash flowreport ↗
2022-Q1—$12M$116M+ $167M short-term inv.$18M-$18M operating cash flowreport ↗
2021-Q3—$9.2M$177M+ $131M short-term inv.$15M-$12M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$70M$38M+ $75M short-term inv.$19M-$74M operating cash flowreport ↗

PMV Pharmaceuticals reported no revenue for the full year ended December 31, 2025. R&D expenses were $69.9M, up 19.4% YoY from $58.5M, while the company posted a net loss of $77.7M, compared with $58.7M in 2024. Cash, cash equivalents, and marketable securities totaled $112.9M at year-end, with an expected cash runway into the end of the second quarter of 2027.

Management guided to a New Drug Application submission for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027, with enrollment on track in the pivotal Phase 2 portion of the PYNNACLE trial. Key developments included FDA Orphan Drug Designation for rezatapopt in TP53 Y220C-positive ovarian cancer, publication of first-in-human data in the New England Journal of Medicine, and updated PYNNACLE results showing a 34% overall response rate across all cohorts and a 46% ORR in the ovarian cancer cohort at the September 4, 2025 data cutoff.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$59M$41M+ $129M short-term inv.$15M-$51M operating cash flowreport ↗
2023-FY—$56M$38M+ $165M short-term inv.$17M-$56M operating cash flowreport ↗
2022-FY—$52M$108M+ $133M short-term inv.$18M-$64M operating cash flowreport ↗
2021-FY—$36M$172M+ $125M short-term inv.$14M-$47M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Eckler Matthew Joseph · directorAward / grant (derivative)84,000——Form 4
2026-06-04BAUM CHARLES M · directorAward / grant (derivative)42,000——Form 4
2026-06-04FLOWERS KIRSTEN · directorAward / grant (derivative)42,000——Form 4
2026-06-04Gallagher Carol Giltner · directorAward / grant (derivative)42,000——Form 4
2026-06-04LEVINE ARNOLD J · directorAward / grant (derivative)42,000——Form 4
2026-06-04Stelzer Laurie · directorAward / grant (derivative)42,000——Form 4
2026-06-04Gallagher Carol Giltner · directorGift (derivative)42,000——Form 4
2026-06-04Gallagher Carol Giltner · directorGift (derivative)42,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 37.0M shares ($43.0M, 48.9% of shares outstanding).

#InstitutionSharesValue
1BML Capital Management, LLC5,320,000$6.6M
2TANG CAPITAL MANAGEMENT LLC4,245,085$5.3M
3Sio Capital Management, LLC3,076,580$3.8M
4ArrowMark Colorado Holdings LLC2,872,764$3.6M
5Euclidean Capital LLC2,627,643$3.3M
6Eversept Partners, LP2,348,360$2.9M
7VANGUARD CAPITAL MANAGEMENT LLC1,974,906$2.4M
8TWO SIGMA INVESTMENTS, LP1,884,530$2.3M
9ADAGE CAPITAL PARTNERS GP, L.L.C.1,860,000$2.3M
10BlackRock, Inc.874,374$1.1M
11MORGAN STANLEY864,311$1.1M
12Stonepine Capital Management, LLC708,102$878K
13Longaeva Partners L.P.552,027$685K
14GEODE CAPITAL MANAGEMENT, LLC495,922$615K
15Aldebaran Capital, LLC473,362$587K